Nitroxide Antioxidant Modulation of UCP2 Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively address irregular gene expression levels, particularly overexpression of uncoupling protein 2 (UCP2), which contributes to various diseases such as cancer, autoimmune disorders, and aging, by not providing a targeted and efficient means to modulate gene expression in human subjects.
Innovation Solution
Administering an effective amount of a nitroxide antioxidant, such as 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl, to human subjects with increased UCP2 expression levels, specifically targeting and decreasing UCP2 gene expression in tissues like skin, adipose, and neuronal tissues, across various age groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural control mechanisms are used to regulate gene expression, then the system is simple and self-regulating, but it fails to correct irregular expression patterns in disease states
Solution Approach 1:
The patent introduces nitroxide antioxidants as intermediary substances that mediate between the body's natural gene expression control mechanisms and the need to correct irregular expression patterns. These antioxidants act as external regulators that can modulate UCP2 gene expression without completely overriding the body's intrinsic control systems, thereby improving reliability while maintaining acceptable complexity
Solution Approach 2:
The patent applies parameter changes by modifying the expression level of the UCP2 gene through nitroxide antioxidant treatment. By changing the expression parameter from overexpressed to normalized levels, the patent addresses the core problem of irregular gene expression in disease states while using a relatively simple intervention approach
2Reliability
If targeted gene therapy is implemented to correct UCP2 overexpression, then disease treatment effectiveness is improved, but the complexity and risk of the therapy increases
Solution Approach 1:
The patent extracts the problematic UCP2 gene expression from the overall cellular system by using nitroxide antioxidants to specifically target and reduce its overexpression. This extraction approach allows for focused treatment of the problematic gene without requiring complex systemic gene therapy interventions, thereby improving treatment effectiveness while managing complexity
Solution Approach 2:
The patent employs nitroxide antioxidants as relatively simple, short-acting molecular agents that can be administered without requiring complex, long-term genetic modification therapies. These antioxidants provide a more straightforward intervention compared to permanent gene editing, reducing the complexity and potential risks associated with targeted gene therapy
3Reliability
If UCP2 expression is reduced to treat diseases, then health outcomes improve, but the mechanism to achieve this reduction is not well-established
Solution Approach 1:
The patent applies the self-service principle by utilizing nitroxide antioxidants that the body can produce or obtain through diet, rather than requiring complex externally manufactured therapies. The body's own antioxidant systems are harnessed to reduce UCP2 overexpression, simplifying the treatment mechanism and improving ease of implementation while maintaining health outcome benefits
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively decreases UCP2 expression levels, thereby reducing the risk and progression of associated diseases, improving mitochondrial function, and potentially curing conditions linked to elevated UCP2 activity.
Implementation Method 1
administering to the human subject an effective amount of a nitroxide antioxidant resulting in a decreased expression level of the gene
Data Source
AI summary
Some embodiments disclosed herein include a method for decreasing an expression level of a gene. The methods can include identifying a human subject having an increased expression level of UCP2; and administering to the human subject an effective amount of a nitroxide antioxidant, whereby expression level of the gene is decreased.